TrialJournal for immunotherapy of cancer2024

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Michael Schenker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.